Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
Klotz L, Chin J, Black PC, Finelli A, Anidjar M, Bladou F, Mercado A, Levental M, Ghai S, Chang SD, Milot L, Patel C, Kassam Z, Moore C, Kasivisvanathan V, Loblaw A, Kebabdjian M, Earle CC, Pond GR, Haider MA. Klotz L, et al. Among authors: moore c. JAMA Oncol. 2021 Apr 1;7(4):534-542. doi: 10.1001/jamaoncol.2020.7589. JAMA Oncol. 2021. PMID: 33538782 Free PMC article. Clinical Trial.
[Focal therapy for prostate cancer: German version].
Kasivisvanathan V, Shah TT, Donaldson I, Kanthabalan A, Moore CM, Emberton M, Ahmed HU. Kasivisvanathan V, et al. Among authors: moore cm. Urologe A. 2015 Feb;54(2):202-9. doi: 10.1007/s00120-014-3668-0. Urologe A. 2015. PMID: 25690574 Review. German.
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium. Drost FH, et al. Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24. Eur Urol. 2019. PMID: 31451332
The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
Stonier T, Simson N, Shah T, Lobo N, Amer T, Lee SM, Bass E, Chau E, Grey A, McCartan N, Acher P, Ahmad I, Arumainayagam N, Brown D, Chapman A, Elf D, Hartington T, Ibrahim I, Leung H, Liyanage S, Lovegrove C, Malthouse T, Mateen B, Mistry K, Morrison I, Nalagatla S, Persad R, Pope A, Sokhi H, Syed H, Tadtayev S, Tharmaratnam M, Qteishat A, Miah S, Emberton M, Moore C, Walton T, Eddy B, Ahmed HU. Stonier T, et al. Among authors: moore c. Eur Urol Focus. 2021 Sep;7(5):1027-1034. doi: 10.1016/j.euf.2020.09.012. Epub 2020 Oct 10. Eur Urol Focus. 2021. PMID: 33046412
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
Bruinsma SM, Nieboer D, Roobol MJ, Bangma CH, Verbeek JFM, Gnanapragasam V, Van Hemelrijck M, Frydenberg M, Lee LS, Valdagni R, Logothetis C, Steyerberg EW; the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Bruinsma SM, et al. J Urol. 2021 Jul;206(1):62-68. doi: 10.1097/JU.0000000000001700. Epub 2021 Feb 22. J Urol. 2021. PMID: 33617330
Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus.
Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, George AK, Gill IS, Gupta RT, Katz AE, Lebastchi AH, Marks LS, Marra G, Pinto PA, Song DY, Sidana A, Ward JF, Sanchez-Salas R, Rosette J, Polascik TJ; Focal Therapy Group Authors. Tan WP, et al. Urol Oncol. 2021 Nov;39(11):781.e17-781.e24. doi: 10.1016/j.urolonc.2021.01.027. Epub 2021 Mar 4. Urol Oncol. 2021. PMID: 33676851 Free PMC article.
Using the Movember Foundation's GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function-a retrospective study in low-risk prostate cancer patients.
Crump RT, Remmers S, Van Hemelrijck M, Helleman J, Nieboer D, Roobol MJ, Venderbos LDF; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Crump RT, et al. Transl Androl Urol. 2021 Jun;10(6):2719-2727. doi: 10.21037/tau-20-1255. Transl Androl Urol. 2021. PMID: 34295757 Free PMC article.
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database.
Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Beckmann K, et al. Eur Urol Open Sci. 2021 Nov 1;34:47-54. doi: 10.1016/j.euros.2021.09.012. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34934967 Free PMC article.
6,190 results